The CID has embedded a number of HIV behavioral research teams within the structure of the provider teams. The projects can provide specialized and intensive assistance to eligible patients.
Project HOPE (NIDA funded)
Project HOPE (Hospital visit as an Opportunity for Prevention and Engagement for HIV-Infected Drug Users). Project HOPE is a three-arm, randomized prospective trial designed to assess the most effective strategy to achieve virologic suppression among hospitalized HIV-infected drug users.
Patients are randomized to one of three arms:
- Treatment as usual
- Patient navigator only
- Patient navigator plus contingency management. Secondary outcomes include linkage and retention in HIV primary care, linkage and retention in drug treatment, and decreased hospitalizations
SPECTRuM (MDPH/HRSA funded)
SPECTRuM (Strategic Peer-Enhanced Care and Treatment Retention Model) is a study that aims to implement service and system-level enhancements to maximize timely linkage to care and treatment for individuals newly diagnosed with HIV infection, those who have fallen out of care, re-engaging in care and/or at high-risk of falling out of care. A linkage and retention team, comprised of a nurse and HIV+ peer, will provide intensive support that helps clients successfully link to care and manage commonly experienced barriers to ongoing engagement in HIV medical care .
Comprehensive Prevention with Positives Intervention (CDC funded)
Research study to test a comprehensive prevention-with-positives intervention to increase retention in HIV care. The research focuses on sexual and drug risk behaviors, retention in care, adherence to treatment regimen, and provision of ART at earlier stages of disease. The study will enroll a cohort of patients for the retention intervention, as well as conduct a clinic-wide, provider-driven intervention.
There will also be a sub-study of patients and their sex partners to examine the effectiveness of an intervention targeted to partners of HIV positive individuals.
Boston ARCH Cohort
Boston ARCH is part of the Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH). The purpose of this study is to observe changes in alcohol and other drug use, HIV disease, physical and mental health, including bone health over time.
Clinical Medication Trials
CID scientists study the way the human body fights viruses like HIV and which parts of our bodies are damaged by HIV. These scientists are trying to discover how to prevent people from contracting the virus, how to minimize the damage caused by the virus, and how to treat the virus more quickly and completely when infection occurs.
AIDS Clinical Trials Group (ACTG)
CID patients can volunteer to try drug treatments that may not yet be available to the general population. All patients have direct access to investigational drug trials, such as the NIH-funded AIDS Clinical Trials Group (ACTG). These experimental drugs are usually free and the effects on, and health of, each volunteer study participant are closely monitored. HIV-negative volunteers are sometimes needed. If you are interested, please call 617-414-7082. By participating in this research, CID patients help others with HIV/AIDS in the global community.
Effect of quadrivalent human papillomavirus (HPV) vaccine, Gardasil™, in Young HIV-positive Males who have Sex with Males.
HIV-positive males who have sex with males (MSM) are at increased risk of developing anal cancer compared with the general population. They are also at high risk of genital warts and anal intraepithelial neoplasia (AIN), the tissue abnormality that leads to anal cancer. The purpose of this study is to determine whether the quadrivalent human papillomavirus (HPV) vaccine, Gardasil™, is safe and effective in young HIV-positive MSM to prevent development of genital warts and AIN.
Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults.
High Grade Intraepithelial Neoplasia (HGAIN) is abnormal tissue in the anal canal caused by Human papillomavirus (HPV). It is more common in men who have sex with men (MSM) and people who are infected with HIV. A few people with HGAIN will develop cancer of the anus.
The physicians and staff of the Center for Infectious Diseases at Boston Medical Center are affiliated with the Boston University School of Medicine (BUSM). To learn about our research, please visit the Infectious Diseases section of the BUSM website.